Boston Scientific Co. (NYSE:BSX) saw unusually large options trading on Thursday. Investors acquired 20,426 call options on the stock. This is an increase of approximately 784% compared to the average volume of 2,310 call options.
Shares of Boston Scientific stock traded up $0.25 during trading on Friday, reaching $38.23. 15,183,927 shares of the company were exchanged, compared to its average volume of 6,665,503. The company has a quick ratio of 1.04, a current ratio of 1.31 and a debt-to-equity ratio of 0.81. Boston Scientific has a twelve month low of $31.56 and a twelve month high of $43.84. The business has a 50-day moving average price of $41.58 and a 200-day moving average price of $40.29. The firm has a market capitalization of $53.25 billion, a price-to-earnings ratio of 26.01, a P/E/G ratio of 2.31 and a beta of 0.78.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. Boston Scientific had a return on equity of 23.29% and a net margin of 13.85%. The business had revenue of $2.63 billion during the quarter, compared to analysts’ expectations of $2.64 billion. During the same period in the previous year, the firm earned $0.41 earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. On average, equities research analysts forecast that Boston Scientific will post 1.56 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. Welch & Forbes LLC grew its stake in Boston Scientific by 0.6% in the third quarter. Welch & Forbes LLC now owns 397,595 shares of the medical equipment provider’s stock valued at $16,179,000 after acquiring an additional 2,375 shares during the period. Pacer Advisors Inc. boosted its position in shares of Boston Scientific by 15.0% during the third quarter. Pacer Advisors Inc. now owns 156,358 shares of the medical equipment provider’s stock worth $6,362,000 after buying an additional 20,342 shares during the period. Artemis Investment Management LLP boosted its position in shares of Boston Scientific by 95.2% during the third quarter. Artemis Investment Management LLP now owns 1,142,569 shares of the medical equipment provider’s stock worth $46,399,000 after buying an additional 557,120 shares during the period. First American Trust FSB boosted its position in shares of Boston Scientific by 1.6% during the third quarter. First American Trust FSB now owns 89,554 shares of the medical equipment provider’s stock worth $3,644,000 after buying an additional 1,367 shares during the period. Finally, CHICAGO TRUST Co NA acquired a new position in shares of Boston Scientific during the third quarter worth about $635,000. 91.47% of the stock is owned by hedge funds and other institutional investors.
BSX has been the topic of several recent analyst reports. Leerink Swann set a $50.00 price target on Boston Scientific and gave the company a “buy” rating in a research note on Wednesday, July 31st. Barclays reiterated an “overweight” rating and issued a $48.00 price objective on shares of Boston Scientific in a research report on Tuesday, September 3rd. Canaccord Genuity lifted their price objective on Boston Scientific from $43.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Stephens set a $48.00 price objective on Boston Scientific and gave the company a “buy” rating in a research report on Monday, September 30th. Finally, ValuEngine downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $45.68.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Story: Accumulation/Distribution
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.